The objective of this study was to determine the effects of hydrogen peroxide alone and in combination with 7,12-dimethylbenza[a]anthracene (DMBA) in the oral cavity because H,O, has been implicated as a complete carcinogen or cocarcinogen in two animal models. In the two independent studies, golden Syrian hamsters were used to evaluate the carcinogenic and cocarcinogenic potential of dentifrices containing H,O, and NaHCO,. In the first study, the cocarcinogenic potential of a dentifrice containing 0.75% H,OJ 5% baking soda was compared with that of a commercial dentifrice with similar ingredients except baking soda and H,O,. In the second study, the cocarcinogenic potential of a dentifrice formulated with 1.5% H,02/7.5% baking soda was compared with a mixture of 3% H,O,/baking soda. All materials were applied to the right cheek pouches of experimental animals, and the left cheek pouches were untreated. In the first study. 0.5% DMBA was administered five times weekly for 20 weeks, and the dentifrices were applied immediately after the DMBA. Dentifrices or mineral oil alone were also applied five times weekly. In the second study. 0.5% DMBA or 0.25% DMBA were applied three times weekly for 16 weeks; dentifrices (or 3% H,O,/baking soda) were applied five times weekly for 16 weeks. The dual-phase dentifrice containing 0.75% H202/5% baking soda was not carcinogenic. and in combination with DMBA resulted in no observable acceleration of tumor onset, compared with DMBA alone. In fact. animals treated with 0.5% DMBA and the H,O,/baking soda dentifrice had a significantly delayed onset of tumor formation than did animals treated with DMBA alone. In the second bioassay, an increased latency period for tumor formation was observed with 0.5% DMBA and a dual-phase dentifrice containing 1.5% H,02/7.5% baking soda, compared with 0.5% DMBA alone. With 0.75% DMBA, latency was not affected by addition of the dualphase dentifrice. In contrast, animals receiving 0.25% DMBA and 3% H,O,/ NaHCO, had a significantly lower rate of tumor formation and overall mass incidence. Croton oil also reduced the rate of tumor formation when applied with 0.25% DMBA. Histopathologic examination of cheek pouches revealed squamous cell carcinomas in the majority of DMBA-treated animals. Cheek
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pouches of DMBA-treated animals killed at interim times indicated a progression from keratotic changes andlor dyskeratosis at 6 weeks with the occurrence of carcinomas in approximately half the animals examined at 12 weeks. No significant histopathologic abnormalities were observed in animals not receiving DMBA other than slight keratosis in the oral mucosa of one or two animals per group. These results demonstrated that an oral product containing baking soda and hydrogen peroxide was not carcinogenic, and that baking soda and H,O, did not enhance the tumorigenicity of DMBA. Furthermore, the tumorigenic response of DMBA was reduced by coadministration of 3% H202 and sodium bicarbonate. Key Words: Hydrogen peroxide-Carcinogenesis-Oral cavity.
Since the early part of this century, hydrogen peroxide and baking soda (NaHC03) have been recommended by dentists as oral health aids (Amigoni et al., 1987) . Consequently, a significant number of people have used hydrogen peroxide and baking soda as an alternative to commercial dentifrices (Wolff et al., 1989) . In one popular regimen, baking soda is mixed with 3% hydrogen peroxide and is used daily instead of commercially available dentifrices. A significant number of people are believed to have used this method during the last 50 years. H202 has also been used as a tooth bleaching aid in cosmetic dentistry since the early 1920s, which has recently been reviewed (Haywood, 1992) .
Hydrogen peroxide is normally present in the body. Some studies have implicated H202 and/or reactive oxygen species in the development of neoplastic disease either by inducing a prooxidant state or by reducing genomic integrity (Cerutti, 1985) . H,02 has also been reported to enhance in vitro cell transformation (Zimmerman and Cerutti, 1984) .
The role of H202 as an antibacterial agent is well established. Accumulation of phagocytic cells and the corresponding release of mediators and active oxygen species results in a transient inflammatory response that diminishes after removal of the foreign material. Levels of H20, released by neutrophils exceed those of monocytes and alveolar macrophages (Ohmann and Babiuk, 1984) . The tumor promoter 12-0-decanoyl phorbol-13-acetate (TPA) also stimulates extracellular oxygen radical formation in neutrophils (Davis et al., 1989) and mononuclear cells (Dull et al., 1987) that can be detected after hydroxylation of the free radical trapping agent salicylate.
Genotoxic responses are seen in oxidant-responsive tester strains of Salmonella typhimurium (Levin et al., 1982) by organic peroxides, Hz02, agents that produce H,O,, and other oxygen radical-generating species. Even in these specially constructed tester strains, H,O, is only weakly positive; organic hydroperoxides are much stronger mutagens (Abu-Shakra and Zeiger, 1990; Kensese and Smith, 1989; Level et al., 1982) .
Because of the growing use of H,O, and its sustained popularity as part of an oral hygiene regimen (the Keyes technique, Keyes et al., 1978) , it is prudent to investigate products containing ingredients that by themselves or in conjunction with known carcinogens have been associated with enhancement of carcinogenesis. An example of such an association is the elevated risk of oropharyngeal cancer development associated with use of mouthrinses containing levels of al-coho1 >25% (Blot, 1992) . Products intended for, or associated with, use in the oral cavity may contain tissue irritants that can induce cellular changes through prolonged chronic irritation.
H202 achieved category I status from the U.S. Food and Drug Administration as a debriding agent for temporary use in the oral cavity (U.S. Code of Federal Regulations, 1988) , which led to the inclusion of H,O, in oral products. In spite of widespread use in the United States and Canada, the European Community has maintained a ban on potentially ingested products that contain or release H2O2 in concentrations >O. 1%. The decision to limit H,O, use was based on studies that have implicated H202 as a carcinogen (Ito et al., 1981) or as a cocarcinogen in the hamster cheek pouch when applied as a 30% solution (Weitzman et al., 1986) . Although these studies have raised valid concerns (Powell and Bales, 1991) , they are inconclusive due to the limited evidence presented and the weakness of the power of the tests from small sample sizes.
Endpoint lesions in the complete carcinogenicity studies of Ito et al. (1981) were hyperplasia, adenomas, and carcinomas. These studies were performed in C57BL/6 mice, a strain that is low in catalase (It0 et al., 1984) , and has a high spontaneous incidence of premalignant duodenal lesions (Rowlatt et al., 1969 (Rowlatt et al., , 1976 .
In the Weitzman study (1986), statistical analyses revealed no difference in mass incidence between groups treated with 0.2% 7,12-dimethylbenza[a]anthracene (DMBA) twice weekly for 19 weeks in the absence or presence of 3% or 30% H20,. After 22 weeks, there was no significant difference between groups receiving 0.2% DMBA and 0.2% DMBA plus 3% H,O,. With 30% H20, and 0.2% DMBA, the tumor incidence at 22 weeks (five of five animals) was greater than that of 0.2% DMBA alone (three of seven animals), but only at a significance level of p = 0.054. Because of the small number of animals and marginal statistical significance, these results provide no substantiation for the cocarcinogenic potential of H2O2. Although exposure to 30% H202 can cause ulceration, primarily marginal and reversible effects were noted at the site of application even after prolonged exposure: 3% H202 had no effect.
This study was undertaken to determine the potential for H,O, to mediate DMBA-induced tumor formation of the buccal cheek pouch in golden Syrian hamsters. The objective was to evaluate oral mucosal irritation and determine the cocarcinogenic potential of dentifrices containing 0.75% H,02/5% NaHCO, or 1.5% H,0,/7.5% NaHCO,. DMBA was used to induce cheek pouch tumors in hamsters, and the effects on tumor formation in the oral rnucosa was determined with concurrent use of a commercial dentifrice with similar ingredients, but without H,O, and baking soda, and dentrifrices containing 0.75% or 1.5% Hz02. Furthermore, the effect of 3% H20, and baking soda on DMBA-induced tumor formation was also determined.
MATERIALS AND METHODS Chemicals and Reagents
DMBA (98 + %) was purchased from Aldrich Chemical Co., Milwaukee, WI, U.S.A. Mineral oil, USP, was provided by Chesebrough-Pond's U.S.A. Co. Re-search Laboratories, Trumbull, CT, U.S.A. The commercial dentifrice, 3% hydrogen peroxide, and baking soda used for comparison were purchased locally. Dual-phase dentifrices consisting of 1.5% hydrogen peroxide in a pluronic gel and 10% sodium bicarbonate in a hydrated silica base or 3% hydrogen peroxide and 15% sodium bicarbonate were prepared by Chesebrough-Pond's U.S.A. Co. Research Laboratories. These dentifrices delivered H202 at levels of 0.75 or 1.5% and NaHCO, at levels of 5 or 7.5% when both phases were mixed; fluoride was delivered at 1150 ppm in both preparations. Peroxide content of H202 and dentifrices was verified before use and at the end of use. Golden Syrian hamsters were obtained from Harlan Sprague Dawley, Inc., Houston, TX, U.S.A. Hamsters were 8-10 weeks of age at the start of the study. When first treated, mean body weights of the animals were 11 1 g (males) and 116 g (females) in the phase I study and 141 g (males) and 137 g (females) in the phase I1 study. Animals were uniquely identified by ear punch, and they were housed individually in wire-bottom suspended stainless steel cages. Teklad Hamster Diet was available ad libitum, and tap water was provided by an automatic watering system. Environmental conditions ranged from 65 to 80°F with a relative humidity of 30-80%, and a 12-h light/dark cycle. National Research Council guidelines for use of animals were followed throughout the study.
Bioassays
In the first study (phase I), animals were treated five times weekly for 20 weeks with each test article as indicated in Table 1. In the second study (phase II), animals were treated three times weekly with DMBA and five times weekly for 16 Dual-phase dentifrices were given as a mixture of 0.1 ml of each component; 3% H,O,/NaHCO, Doses were administered three times weekly for DMBA and five times weekly for dentifrices for killed.
(Phase 11) was given as 0.2 ml of a mixture of equal amounts of both components.
16 weeks. Surviving animals were killed 20 weeks from initial dosing. Vol. 15. No. I , 1996 H202-CONTAINING DENTIFRICE: COCARCINOGENICITY 49 weeks with dentifrices as indicated in Table 1 . Mortality checks were made daily, whereas toxicity (emaciation. salivation, ataxia, etc.) was noted weekly. Cheek pouches were examined weekly for erythema, edema, ulceration, irritation, and papilloma formation. Gross necropsies were conducted on all animals that died during the study unless autolysis was excessive, on animals killed at 6 or 12 weeks, and on animals that survived until study termination. Cheek pouches, gross lesions, tongues, palates, and forestomachs were saved in 10% neutral buffered formalin unless advanced autolysis had occurred. Cheek pouches were sectioned and embedded; slides were stained with hematoxylin and eosin for evaluation of the oral mucosa. The slides were read by a veterinary pathologist without knowledge of the treatment groups.
Animal Randomization, Weight Determination, and Dosing
Hamsters were acclimated for 1 week before baseline weight determinations were made 1 week before dosing and again on the date of first treatment. All cheek pouches were examined before initial dosing, and hamsters with mucosal irritation were not used for the study. On the day before the first treatment, animals were randomized by group to within *20% of the mean weight for each sex; body weights of surviving animals were recorded weekly throughout the studies. All surviving animals in each treatment group were dosed as indicated in Table 1 . Dual-phase dentifrices and 3% H,02/NaHC0, were mixed immediately before dosing. Materials were introduced into cheek pouches by syringe in 0.1-ml amounts (or 0.2 ml for two-component mixtures), and they were spread over the pouches with a camel hair brush (phase I) or cotton swab (phase 11). Each animal had its own brush for the duration of the phase I study: swabs were disposed of after each animal was treated (phase 11). The swabs were prewetted with mineral oil before use. Dosing solutions were used within 2 weeks of preparation, and they were stable during the period of use. Concentrations were verified by absorbance at 362 nm before use and at the end of dosing. Analyses of DMBA dosing solutions were 0.518 * 0.043% in phase I and 0.255 ? 0.015% or 0.510 -+ 0.035% (mean -+ SD) in phase 11. Two hamsters per sex per group were killed after 6 and 12 weeks for histopathologic evaluation of cheek pouches (phase I).
Statistical Analyses
The study endpoint was defined as the time to first occurrence of a papilloma in an animal's cheek pouch. The log rank test was used to compare the survival (i.e., tumor-free) experience of animals treated with DMBA alone with animals in each of the remaining experimental groups. Animals that died before developing a tumor were right-censored. Kaplan-Meier survival estimates were used to compare the latency periods for tumor formation. Statistical analyses were done at significance levels of p < 0.05 or p < 0.01.
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RESULTS
General Observations
In general, animals treated with DMBA exhibited eschar and alopecia around the mouth. When tumors in the cheek pouch became established, general signs of poor health, such as decreased activity and emaciation, were observed. Animals treated with the dual-phase dentifrice alone or with mineral oil had few clinical signs. Survival was increased in phase 11, in which DMBA dosing was decreased from five to three times weekly ( Table 2) .
Few animals in the initial study survived until terminal killing, except vehicle control and dentifrice without DMBA treatment groups. The DMBA dose intensity in the phase I study produced significantly earlier deaths compared with the second study, in which DMBA administration was reduced. The average total DMBA dose in phase I was 42 mglanimal, based on 0.518 mglday, 5 dayslweek, and an average life span of 16.2 weeks.
DMBA administration was discontinued after 16 weeks in phase 11. In the phase I1 study, nearly half of the animals that received 0.5% DMBA survived until terminal killing at 20 weeks. Toxicity with 0.5% DMBA administration was more apparent in females compared with males in the phase I1 study. Animals given Twenty-five animals/group at start of bioassay; twolsexlgroup killed at 6 and 12 weeks in phase I bioassay only; presumed dead includes animals that escaped from cages and were not located; number dead includes moribund killings. Number treated excludes animals from interim killing and animals presumed dead. Toxicol, Vol. 15, N o . I, 1996 H,O,-CONTAINING DENTIFRICE: COCARCINOGENZCITY 51 0.5% DMBA had a total DMBA exposure of 24 mg, and animals given 0.25% DMBA had a total DMBA exposure of 12 mg. The dual-phase dentifrice alone did not affect survival. Survival was similar in the DMBA and hydrogen peroxide/ NaHCO, group, compared with animals receiving DMBA alone.
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Observance of Cheek Pouch Masses
Phase I Bioassay
Oral lesions (papillomas) were first consistently observed in week 10. As can be seen in Fig. 1 , almost 30% of the animals treated with 0.5% DMBA alone had developed a mass by the end of week 10 after a total DMBA dose of 25.9 mg. Changes in the oral mucosa ranged from inflammation to keratosis to carcinoma with time, as is usually observed in hamster cheek pouches treated with DMBA.
The log rank test is widely recommended for statistical comparison of groups of observations of event times in which some observations may be censored. It is the rank test of greatest local power for detecting multiplicative differences in failure rates (e.g., the first occurrence of a tumor), and it is used in clinical trials and carcinogenesis studies. Following Pet0 and Pike (1973) , the approximation (0-E)'/E can be used as a conservative alternative to the usual test for heterogeneity. This approximation was used to compare tumor-free survival of the DMBAtreated group with each of the other treatment groups. Animals that died before developing a tumor or escaped were right-censored. Kaplan-Meier estimates of survival (time to tumor) for the groups were also calculated (Fig. 2) . Hamsters in two of the test groups (dual-phase dentifrice alone and mineral oil alone) had no evidence of cheek pouch masses by the end of the study (Table 3) . Cumulative mass incidence in hamsters treated with 0.5% DMBA. 0.5% DMBNcommercial dentifrice, or 0.5% DMBA/0.75% H202/5% NaHCO, dual phase dentifrice (Phase I). Table 3 are presented in Table 4 . The null hypothesis of no difference in tumor development rate between 0.5% DMBA alone and each of the groups that were treated with 0.5% DMBA and dentifrice was tested. The significance level a = 0.05 was adjusted for multiple comparisons to 0.01. The mass incidence rate for animals in the 0.5% DMBNcommercial dentifrice group was not statistically significantly different from that of animals receiving 0.5% DMBA alone. The mass incidence -ate for animals in the 0.5% DMBA/dual-phase dentifrice was statistically signifcantly lower than that of animals in the 0.5% DMBA group.
To ensure that these conclusions were not affected by censoring (i.e., deaths 3efore mass occurrence), the log rank test was applied to the modified data in which all censoring times were assumed to be "event times." Animals that died without developing a mass, those lost to follow-up, and those killed at 6 and 12 weeks were censored. The modified data are presented in Table 5 , and log rank .est analyses are presented in Table 6 . As seen in Table 6 , the pattern of censoring iad no effect on conclusions drawn from the data.
Phase II Bioassay
As observed in phase I, the latency period for mass formation in phase I1 (Fig.  3) was significantly increased in animals given 0.5% DMBA and dual-phase denifrice with 1.5% Hz0,/7.5% NaHCO,, compared with 0.5% DMBA alone ( Table  7) . Although the mass incidence rate was slightly lower in the 0.25% DMBA/dual-3hase dentifrice group, this difference was not statistically significant from the 1.25% DMBA group (Table 8) . A significantly lower mass incidence rate was seen with 0.25% DMBA/3% H,O, + NaHCO, and 0.25% DMBA/I% croton oil, com-Jared with 0.25% DMBA alone. The overall tumor incidence was the same in 0.25% DMBA or 0.25% DMBA and dual-phase dentifrice treatment groups from Kaplan-Meier survival curves (Fig. 4) .
Histopathology
Histopathologic evaluation of cheek pouches of DMBA-treated groups killed at interim times indicated a progression from keratotic changes and/or dyskeratosis at 6 weeks to the occurrence of carcinoma in -50% of animals examined at 12 weeks. Only keratotic lesions were seen in cheek pouches of one animal treated with mineral oil and two animals treated with dual-phase dentifrice alone. Tumors were observed in untreated cheek pouches, which can occur when food is transferred from treated pouches to untreated pouches after DMBA administration. pouches of animals that died or were killed are presented in Table 9 (phase I) and
Results of histopathologic examination and categorization of treated cheek
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Table 10 (phase 11). Carcinomas identified in the cheek pouches of animals given DMBA were mostly of squamous cell origin. There was no significant difference in the number of tumor-bearing animals that received DMBA or DMBA and dentifrices. Significantly fewer tumor-bearing animals were found in the 0.25% DMBA/3% H,0, + NaHCO, and 0.25% DMBA/l% croton oil groups, compared with 0.25% DMBA alone.
DISCUSSION
Long-term clinical studies have not shown a positive association between chronic use of hydrogen peroxide (~3 % ) and the presence of gingival or buccal tumors in human subjects. However, animal studies have implicated H,O-, as a cocarcinogen in the hamster cheek pouch (Weitzman et al., 1986) . a weak tumor promoter in mouse skin (Klein-Szanto and Slaga, 19821 , and a complete gastrointestinal carcinogen in the mouse (Ito et al., 1981) . In mouse skin, H,O, was reported to be a weak tumor promoter, and a 6% papilloma incidence occurred after twice weekly H,O, administration for 25 weeks after DMBA (Klein-Szanto and Slaga, 1982) . In contrast, animals receiving 30% H2O2 had a lower papilloma incidence than animals receiving 6% H,O,. This observation was thought to result from toxic effects of 30% H20, on initiated skin cells. Based on a conversion factor from papillomas to carcinomas of 12%, the overall skin tumor incidence for TPA would be nearly 100 times greater than that expected from H20, at a thousandfold lower dose of TPA.
Oral cavity tumors can be induced in rodents by exposure to smokeless tobacco products (Hecht et al., 1986) , but there are few reports of tumor promotion in this animal model. In one study, 0.1% DMBA was administered to the cheek pouches of hamsters for 10 weeks, followed by 0.5% DMBA for 5 weeks (Odukoya and Shklar, 1982) . Because neither dose intensity alone was sufficient to induce tumors, the presence of tumors in the animals receiving 0.1% DMBA followed by 0.5% DMBA suggests DMBA also has tumor-promoting activity in the hamster cheek pouch.
Enhanced tumor response (cocarcinogenicity) was reported in hamster cheek pouches with concurrent radiation (Lurie, 1977) , wounding (Renstrup et al., 1962) , or ethanol exposure (Freedman and Shklar, 1978) . Thus, this animal model has proven utility in identifying cocarcinogens in the oral mucosa.
In another study (Padhma et al., 1989) , 30% H,O, was reported to increase the cheek pouch tumor incidence in hamsters treated with the tobacco-specific nitrosamine 4-(methylnitrosamino)-l-(3-pyridyl)-l-butanone (NNK) either in a cocarcinogenic or tumor-promoting regimen. The end point achieved in the latter study, papillary hyperplasia of the cheek pouch, is a reversible, benign, or preneoplastic condition. Because papillary hyperplasia is reversible, these results provide fur- ther evidence that minimal responses are obtained after exposure to 30% H,O,. No squamous cell carcinomas were observed in the target tissue (hamster cheek pouch), but lung adenomas and hepatomas were increased in animals receiving NNK and 30% H,O,.
A commercial dentifrice with similar levels of silica abrasive, common flavoring system components, and sodium lauryl sulfate was used in this study to rule out the possibility of dilution or mechanical irritation by a dentifrice when administered with DMBA. Although sodium lauryl sulfate and silica abrasives are mild irritants at higher levels, no irritation was seen in animals treated with the 0.75% H,O,-containing dentifrice or the commercial dentifrice.
The reduction in tumor incidence rate after coadministration of the dual-phase dentifrice and 0.5% DMBA was not likely due to a dilution effect of DMBA over a wider surface area, or from DMBA sequestration within the dentifrice matrix. The increased latency observed with the dual-phase dentifrice also cannot be explained by degradation of DMBA, because treatment of DMBA with up to 3% H202 or with the dual-phase dentifrice did not result in degradation (data not shown).
There were no gross observations of lesions in the intestinal tracts of any animals in this study. In the Ito study (Ito et al., 19811 , animals received 0.4% H,O, in the drinking water for 10 weeks before developing gastric lesions. Assuming a daily water consumption of 2 mliday, the dose intensity of H,O, exposure was -560 mg during this period. In hamsters given the 0.75% H,O,/NaHCO, dentifrice alone via the cheek pouch, H20, exposure was -120 mg based on an average survival of 16 weeks. Animals given the 1.5% H,O,-containing dentifrice or 3% H20, and baking soda received 240 mg H,O, during the 16-week exposure.
The increased latency in tumor formation in animals receiving DMBA and dual-phase dentifrices could be explained by protective effects of dentifrice constituents. Alternatively, 0.75% or 1.5% H,O, were subthreshold doses, as previously reported in this animal model for 3% H20, (Weitzman et al., 1986) . The dual-phase dentifrices are not mutagenic, and they can reduce hydroxyl freeradical formation (Marshall et al., 1994a (Marshall et al., , 1994b . Antioxidants (e.g., glutathione), extracellular defenses such as salivary peroxidase (Carlsson, 1987) , and detoxification enzymes (e.g., catalase and superoxide dismutase) can further reduce levels of reactive oxygen species.
Because little inflammation was observed in any of the treatment groups, the contribution of free radicals and other reactive oxygen species from phagocytic cells or the dentifrices was negligible. Indirect evidence of the lack of involvement of active oxygen species in the cheek pouch epithelium after administration of the dual-phase dentifrices was provided by histologic findings of a lack of phagocyte infiltration of the mucosa. Release of active oxygen species by phagocytes leads to recruitment of additional phagocytes when reactive oxygen species are present. Histologically, phagocytes were not recruited in the buccal mucosa by 3% H 2 0 2 or by the levels of hydrogen peroxide present in any of the dentifrice formulations. Oral irritation was also not observed in an 18-month clinical study of a mouth rinse containing 0.05% NaF and 1.5% H,O, as a decalcification preventative in orthodontically banded subjects (Boyd, 1989) . Furthermore, the oral health of sub-
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jects in the H202-treated group was significantly better. Our results in hamsters are consistent with observations from clinical studies with human subjects that mucosal irritation is not observed with low levels of hydrogen peroxide (Marshall et al., 1995) .
When hamsters 12-14 months of age were treated simultaneously with DMBA and 1% croton oil, a cocarcinogenic effect was observed in the cheek pouch (Silberman and Shklar, 1963) ; this effect was not seen in hamsters 2-3 months of age at the time of treatment. In our study, cocarcinogenicity was not observed with hamsters treated with 1% croton oil and 0.25% DMBA. Furthermore, no irritation was observed in hamster cheek pouches after exposure to 1% croton oil, in contrast to the severe effects reported by Silberman and Shklar (1963) . The lack of an effect with croton oil could be due to differences in composition of this natural product or insensitivity of hamster cheek pouch epithelium to croton oil components such as TPA, as has previously been reported (Gimenez-Conti and Slaga, 1992; Sisskin and Barrett, 1981) . In mouse skin, croton oil and TPA produce an inflammatory response followed by sustained hyperplasia. Although severe irritation was not observed with DMBA and croton oil in our study, the hamsters used in our study were of a similar age as those reported by Silberman and Shklar (1963) to have delayed tumor onset with DMBA and croton oil coadministration.
In conclusion, results from this study demonstrated that a dual-phase dentifrice containing 5% baking soda and 0.75% H202 was not carcinogenic, and that dualphase dentifrices containing 0.75% or 1.5% H202 and baking soda did not enhance the rate of hamster cheek pouch tumor formation by DMBA. In fact, a reduction in the rate of tumor onset was observed in animals treated with 0.5% DMBA and the dual-phase dentifrices, compared with 0.5% DMBA alone, or with 0.5% DMBA and a commercial dentifrice. An even greater reduction in DMBAmediated tumor formation was noted with 3% H202 and sodium bicarbonate, compared with DMBA and dual-phase dentifrices. These results support previous studies in which minimal or no effects were observed in the oral mucosa after exposure to 3% hydrogen peroxide in the presence or absence of known carcinogens.
